Sign up
Pharma Capital

OptiBiotix extends LPLDL supply agreement with German probiotics firm HLH

Under the terms of the new deal, HLH will have to double its order volume every year for three years if it wants to maintain exclusivity over LPLDL in Germany
cholesterol
HLH is one of Europe’s leading suppliers of probiotics to the pharmacy market

OptiBiotix Health plc’s (LON:OPTI) subsidiary, ProBiotix Health, has extended its original supply agreement with German probiotics supplier HLH Biopharma.

The new three-year agreement grants HLH an exclusive licence to produce, package and commercialise a capsule containing Opti’s cholesterol-reducing LPLDL strain in Germany.

In order to maintain exclusivity in Germany, HLH will have to double its order volumes every year.

READ: OptiBiotix Health’s cholesterol product recognised as safe by expert US panel

As part of the tie-up, HLH has also been granted a non-exclusive licence to produce, package and commercialise products containing LPLDL in Austria, Switzerland and the United Arab Emirates.

“We are pleased to announce this extension of terms and territory with HLH who is one of Europe's leading suppliers of probiotics to the pharmacy market,” said chief executive Stephen O’Hara.

“The agreement recognises the success of HLH in building sales of its LPLDL containing Lactobact brand in Germany and extends the terms and territory to support further sale growth.

“This is another step in extending the geographical reach of LPLDL as it builds recurring revenue streams and increases brand recognition and the value of its products.

“This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world.”

View full OPTI profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.